Previous Close | 4.51 |
Open | 4.48 |
Bid | 4.36 x 100 |
Ask | 5.68 x 200 |
Day's Range | 4.36 - 4.58 |
52 Week Range | 3.75 - 19.47 |
Volume | 780,190 |
Avg. Volume | 1,166,572 |
Market Cap | 166.83M |
Beta | 1.39 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
NewLink toppled Monday after it scrapped a late-stage study of its immuno-oncology drug in combination with drugs from Merck and Bristol.
NewLink Genetics Corp. shares fell as much as 15% in premarket trade Monday after the company said it won't proceed as planned with a late-stage trial of its indoximod for advanced melanoma. The company ...
Shares of NewLink Genetics Corp. (NLNT) plunged about 42.6% following the news of the failure of Incyte and Merck's phase III combination study for metastatic melanoma.
Argus raises IQVIA Holdings Inc. (NYSE: IQV ) price target from $110 to $112, says contract research organizations will benefit from “steady biopharmaceutical funding and a healthy backlog”; Firm raises ...
NewLink Genetics Corp (NASDAQ: NLNK ) said Friday it will review the clinical programs for its indoximod therapy after rival Incyte Corporation (NASDAQ: INCY ) announced disappointing results from a study ...
NewLink Genetics Corp (NASDAQ: NLNK ), a late-stage biopharmaceutical company that focuses on cancer treatments, said on Friday it will review its clinical program after Merck & Co., Inc. (NYSE: MRK ) ...
Incyte's (INCY) epacadostat in combination with Merck's Keytruda fails to meet primary endpoint of PFS in a phase III melanoma study.
NewLink Genetics Corp. plans to review its clinical programs after the failure of a similar drug in a Merck and Incyte clinical trial. NewLink noted that the mechanism of its drug, an IDO pathway inhibitor ...
These headlines first appeared on Benzinga Pro . Cantor out defending NewLink Genetics Corp (NASDAQ: NLNK ), says indoximod is differentiated vs epacadostat in response rates in more heavily pretreated ...
There's bad news on the clinical trial front.
NewLink Genetics Corp. shares plummeted 39.2% in premarket trade Friday after Merck and Incyte Corp. said their trial testing a combination including a type of cancer drug called an IDO inhibitor had failed. ...
Surging implied volatility makes NewLink Genetics (NLNK) stock lucrative to the option traders.
Q4 2017 NewLink Genetics Corp Earnings Call
The Ames, Iowa-based company said it had a loss of 37 cents per share. The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss ...
It’s no secret that hedge funds have been underperforming the market by quite a wide margin in the last couple of years. However, in the industry that encompasses hundred of hedge funds and has gathered over $3.0 trillion in assets under management, there still are many players that posted great returns. This is particularly the […]
The latest earnings announcement NewLink Genetics Corporation’s (NASDAQ:NLNK) released in September 2017 suggested that losses became smaller relative to the prrior year’s level as a result of recent tailwinds TodayRead More...
Q3 2017 NewLink Genetics Corp Earnings Call
The Ames, Iowa-based company said it had a loss of 69 cents per share. The results exceeded Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for ...
The U.S. Food and Drug Administration has granted orphan drug designation to NewLink's indoximod, a potential treatment for patients with Stage IIb-IV melanoma.
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to NewLink Genetics Corp. Here are 5 ETFs with the largest exposure to NLNK-US. Comparing the performance and risk of NewLink Genetics Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
Reasoning that NewLink Genetics Corp (NASDAQ: NLNK ) shares are undervalued, Bank of America Merrill Lynch initiated coverage at Buy with a $22 price target. At time of writing, shares were rallying 8.45 ...
New data on NewLink's lead drug puts some pep in this clinical-stage drug developers' step.
An anticipated secondary offering appears to be priced better than expected.
NewLink Genetics Corporation (NASDAQ:NLNK) announced a loss of -$66.69M in its most recent earnings update. Although some investors expected this, their belief in the path to profitability for NLNK mayRead More...
Q2 2017 NewLink Genetics Corp Earnings Call